The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study

Deepak L Bhatt; Guillaume Paré; John W Eikelboom; Katy L Simonsen; Eileen S Emison; Keith A A Fox; Ph Gabriel Steg; Gilles Montalescot; Nihar Bhakta; Werner Hacke; Marcus D Flather; Koon-Hou Mak; Patrice Cacoub; Mark A Creager; Peter B Berger; Steven R Steinhubl; Gurunathan Murugesan; Shamir R Mehta; Kandice Kottke-Marchant; A Michael Lincoff; Eric J Topol; CHARISMA Investigators

doi:10.1093/eurheartj/ehs059

The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study

Deepak L Bhatt, Guillaume Paré, John W Eikelboom, Katy L Simonsen, Eileen S Emison, Keith A A Fox, Ph Gabriel Steg, Gilles Montalescot, Nihar Bhakta, Werner Hacke, Marcus D Flather, Koon-Hou Mak, Patrice Cacoub, Mark A Creager, Peter B Berger, Steven R Steinhubl, Gurunathan Murugesan, Shamir R Mehta, Kandice Kottke-Marchant, A Michael LincoffEric J Topol, CHARISMA Investigators

Research output: Contribution to journal › Article › peer-review

91 Citations (Scopus)

Abstract

Clinical trials have established the value of clopidogrel therapy in a wide spectrum of patients with cardiovascular diseases. Both loss- and gain-of-function single nucleotide variants of CYP2C19 genes have been identified that affect clopidogrel metabolism and anti-platelet response. We sought to determine the impact of CYP2C19 polymorphisms on ischaemic and bleeding events.

Original language	English
Pages (from-to)	2143-50
Number of pages	8
Journal	European Heart Journal
Volume	33
Issue number	17
DOIs	https://doi.org/10.1093/eurheartj/ehs059
Publication status	Published - Sep 2012

Keywords

Aryl Hydrocarbon Hydroxylases
Atherosclerosis
Female
Genotype
Hemorrhage
Heterozygote
Humans
Ischemia
Kaplan-Meier Estimate
Male
Middle Aged
Myocardial Infarction
Platelet Aggregation Inhibitors
Polymorphism, Genetic
Stroke
Thrombosis
Ticlopidine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/eurheartj/ehs059

Cite this

Bhatt, D. L., Paré, G., Eikelboom, J. W., Simonsen, K. L., Emison, E. S., Fox, K. A. A., Steg, P. G., Montalescot, G., Bhakta, N., Hacke, W., Flather, M. D., Mak, K-H., Cacoub, P., Creager, M. A., Berger, P. B., Steinhubl, S. R., Murugesan, G., Mehta, S. R., Kottke-Marchant, K., ... CHARISMA Investigators (2012). The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. European Heart Journal, 33(17), 2143-50. https://doi.org/10.1093/eurheartj/ehs059

Bhatt, Deepak L ; Paré, Guillaume ; Eikelboom, John W ; Simonsen, Katy L ; Emison, Eileen S ; Fox, Keith A A ; Steg, Ph Gabriel ; Montalescot, Gilles ; Bhakta, Nihar ; Hacke, Werner ; Flather, Marcus D ; Mak, Koon-Hou ; Cacoub, Patrice ; Creager, Mark A ; Berger, Peter B ; Steinhubl, Steven R ; Murugesan, Gurunathan ; Mehta, Shamir R ; Kottke-Marchant, Kandice ; Lincoff, A Michael ; Topol, Eric J ; CHARISMA Investigators. / The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients : the CHARISMA genetics study. In: European Heart Journal. 2012 ; Vol. 33, No. 17. pp. 2143-50.

@article{67d64bc287bc4dacad964ba7624aadc8,

title = "The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study",

abstract = "Clinical trials have established the value of clopidogrel therapy in a wide spectrum of patients with cardiovascular diseases. Both loss- and gain-of-function single nucleotide variants of CYP2C19 genes have been identified that affect clopidogrel metabolism and anti-platelet response. We sought to determine the impact of CYP2C19 polymorphisms on ischaemic and bleeding events.",

keywords = "Aryl Hydrocarbon Hydroxylases, Atherosclerosis, Female, Genotype, Hemorrhage, Heterozygote, Humans, Ischemia, Kaplan-Meier Estimate, Male, Middle Aged, Myocardial Infarction, Platelet Aggregation Inhibitors, Polymorphism, Genetic, Stroke, Thrombosis, Ticlopidine",

author = "Bhatt, {Deepak L} and Guillaume Par{\'e} and Eikelboom, {John W} and Simonsen, {Katy L} and Emison, {Eileen S} and Fox, {Keith A A} and Steg, {Ph Gabriel} and Gilles Montalescot and Nihar Bhakta and Werner Hacke and Flather, {Marcus D} and Koon-Hou Mak and Patrice Cacoub and Creager, {Mark A} and Berger, {Peter B} and Steinhubl, {Steven R} and Gurunathan Murugesan and Mehta, {Shamir R} and Kandice Kottke-Marchant and Lincoff, {A Michael} and Topol, {Eric J} and {CHARISMA Investigators}",

year = "2012",

month = sep,

doi = "10.1093/eurheartj/ehs059",

language = "English",

volume = "33",

pages = "2143--50",

journal = "European Heart Journal",

issn = "0195-668X",

publisher = "Oxford University Press",

number = "17",

}

Bhatt, DL, Paré, G, Eikelboom, JW, Simonsen, KL, Emison, ES, Fox, KAA, Steg, PG, Montalescot, G, Bhakta, N, Hacke, W, Flather, MD, Mak, K-H, Cacoub, P, Creager, MA, Berger, PB, Steinhubl, SR, Murugesan, G, Mehta, SR, Kottke-Marchant, K, Lincoff, AM, Topol, EJ & CHARISMA Investigators 2012, 'The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study', European Heart Journal, vol. 33, no. 17, pp. 2143-50. https://doi.org/10.1093/eurheartj/ehs059

The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients : the CHARISMA genetics study. / Bhatt, Deepak L; Paré, Guillaume; Eikelboom, John W; Simonsen, Katy L; Emison, Eileen S; Fox, Keith A A; Steg, Ph Gabriel; Montalescot, Gilles; Bhakta, Nihar; Hacke, Werner; Flather, Marcus D; Mak, Koon-Hou; Cacoub, Patrice; Creager, Mark A; Berger, Peter B; Steinhubl, Steven R; Murugesan, Gurunathan; Mehta, Shamir R; Kottke-Marchant, Kandice; Lincoff, A Michael; Topol, Eric J; CHARISMA Investigators.

In: European Heart Journal, Vol. 33, No. 17, 09.2012, p. 2143-50.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients

T2 - the CHARISMA genetics study

AU - Bhatt, Deepak L

AU - Paré, Guillaume

AU - Eikelboom, John W

AU - Simonsen, Katy L

AU - Emison, Eileen S

AU - Fox, Keith A A

AU - Steg, Ph Gabriel

AU - Montalescot, Gilles

AU - Bhakta, Nihar

AU - Hacke, Werner

AU - Flather, Marcus D

AU - Mak, Koon-Hou

AU - Cacoub, Patrice

AU - Creager, Mark A

AU - Berger, Peter B

AU - Steinhubl, Steven R

AU - Murugesan, Gurunathan

AU - Mehta, Shamir R

AU - Kottke-Marchant, Kandice

AU - Lincoff, A Michael

AU - Topol, Eric J

AU - CHARISMA Investigators

PY - 2012/9

Y1 - 2012/9

N2 - Clinical trials have established the value of clopidogrel therapy in a wide spectrum of patients with cardiovascular diseases. Both loss- and gain-of-function single nucleotide variants of CYP2C19 genes have been identified that affect clopidogrel metabolism and anti-platelet response. We sought to determine the impact of CYP2C19 polymorphisms on ischaemic and bleeding events.

AB - Clinical trials have established the value of clopidogrel therapy in a wide spectrum of patients with cardiovascular diseases. Both loss- and gain-of-function single nucleotide variants of CYP2C19 genes have been identified that affect clopidogrel metabolism and anti-platelet response. We sought to determine the impact of CYP2C19 polymorphisms on ischaemic and bleeding events.

KW - Aryl Hydrocarbon Hydroxylases

KW - Atherosclerosis

KW - Female

KW - Genotype

KW - Hemorrhage

KW - Heterozygote

KW - Humans

KW - Ischemia

KW - Kaplan-Meier Estimate

KW - Male

KW - Middle Aged

KW - Myocardial Infarction

KW - Platelet Aggregation Inhibitors

KW - Polymorphism, Genetic

KW - Stroke

KW - Thrombosis

KW - Ticlopidine

U2 - 10.1093/eurheartj/ehs059

DO - 10.1093/eurheartj/ehs059

M3 - Article

C2 - 22450429

VL - 33

SP - 2143

EP - 2150

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 17

ER -